ARAY logo

ACCURAY INC

ARAYNASDAQ
πŸ† #4135 by market capEarnings Aug 12US Equity
$0.28β–Ό $0.01 (βˆ’1.90%)
Live
1hβ–² 3.1%
24hβ–Ό 1.9%
7dβ–² 1.4%
14dβ–² 22.2%
30dβ–² 3.3%
1yβ–Ό 80.9%
🏦Market Cap
$34M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+2.7%
Slowing
πŸ“ŠGross Margin
26.8%
Moderate
πŸ’΅FCF Margin
-6.8%
Thin
βš–οΈP/S Ratio
0.1x
Cheap
Otter Score
46
Weak

Trading Snapshot

Day Range
$0.28 – $0.29
52-Week Range
$0.22 – $2.10
Volume
$3.12B
Avg Volume
$2.65B
Shares Outstanding
119.0M
Next Earnings
Oct 4, 2026

Fundamentals Snapshot

Annual Revenue
$459M
Last Q Revenue
$105M
P/E Ratio
-0.8
P/S Ratio
0.1x
EPS (TTM)
$-0.37
Dividend Yield
0.00%

Why Investors Own ARAY

  • βœ“High-growth profile β€” revenue up +11.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 77% gross margin and 27% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$459Mβ–² +6.3% YoY
Gross Margin (TTM)
77.2%β–² +2.7% YoY
Operating Income (TTM)
$169Mβ–² +6.3% YoY
Free Cash Flow (TTM)
$126Mβ–² +6.3% YoY

About ACCURAY INC

Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
46/100

Analyst Price Target

β“˜
Average Target
$0.38
β–² +32.1% Upside
High Target$0.43
Low Target$0.31
Based on 31 analysts

Latest News & Updates